AusCann (ASX: AC8)

AusCann (ASX: AC8) aims of producing and providing high quality, economical and clinically validated cannabis medicines to patients. Bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products and has built a strong team of experts and partners with international connections. www.auscann.com.au

TGA cannabis changes pot stocks Therapeutic Goods Administration cannabidiol CBD over-the-counter OTC

Drawbacks of the TGA’s cannabis changes for listed pot stocks

Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator...
AusCann ASX AC8 hard shell capsule clinical trial cannabis CBD TGA

AusCann to begin distributing THC-CBD medicinal cannabis capsules throughout Australia

AusCann Group’s (ASX: AC8) hard shell medicinal cannabis products are now available for prescription Australia-wide, with clinical trials also r...
AusCann ASX AC8 medical cannabis capsules

AusCann fast-tracks commercialisation of cannabinoid capsules

AusCann Group Holdings (ASX: AC8) is speeding up plans to bring its proprietary cannabinoid-based hard-shell capsules to market, aiming to make ...
AusCann Group ASX AC8 purchase medical cannabis research and development Facility Perth

AusCann Group finalises purchase of medical cannabis R&D facility in Perth

Medical cannabis company AusCann Group (ASX: AC8) has taken an assertive step into expanding its production business by acquiring a 7,300-square...
AusCann ASX AC8 Dayacann cannabis Khiron Life Sciences

AusCann looks to tighten grip on Latin American medicinal cannabis growth spurt

One of Australia’s most prominent medical cannabis growth stories AusCann (ASX: AC8) has announced that its Chilean joint venture company DayaCa...
AusCann ASX AC8 API successful pilot study cannabinoid capsule marijuana medical

AusCann reports successful study in ‘game changer’ cannabinoid capsules

AusCann (ASX: AC8) is a step closer to releasing its proprietary cannabinoid capsules to world markets after a “successful” pilot study into its...
AusCann ASX AC8 medical cannabis footprint Canada Australia

AusCann grows its medical cannabis footprint in Canada and Australia

Not long after completing its second harvest in Chile, pharmaceutical company AusCann Group (ASX: AC8) has made plans to accelerate its cultivat...
AusCann ASX AC8 medical cannabis second harvest Chile

AusCann steps up medical cannabis growing operation in Chile

Medicinal cannabis commerciality continues to bloom in all continents, as South America adds its voice to growing calls for public acceptance of...
Auscann ASX AC8 API Australian Pharmaceutical Industries distribution agreement

AusCann strikes distribution agreement with ASX-listed Australian Pharmaceutical Industries

AusCann Group (ASX: AC8), a leading Australian medicinal cannabis company, has announced a Heads of Agreement (HoA) with ASX-listed Australian P...
AusCann ASX AC8 plants second cannabis crop Chile DayaCann

AusCann plants second cannabis crop in Chile

AusCann (ASX: AC8) has announced the planting of a second medicinal cannabis crop in Chile, with harvest expected in the first half of next year...
AusCann ASX AC8 Chile joint venture cannabis cultivation DayaCann Fundacion Daya

AusCann’s Chilean JV fires up for another year of cannabis cultivation

AusCann Group Holdings (ASX: AC8) has acquired another one-year licence allowing it to cultivate cannabis crops at its 50%-owned facility in Chi...
Small Caps ASX Australian stock market
Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
Copyright 2020 Small Caps. All rights reserved.